Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Almotriptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D known ✓ | P28221 | 4/20 | 0.64 |
| ▸ | HTR1B known ✓ | P28222 | 4/20 | 0.64 |
| ▸ | HTR1F known ✓ | P30939 | 1/20 | 0.64 |
| ▸ | HTR1A | P08908 | 7/20 | 0.98 |
| ▸ | HTR2A | P28223 | 3/20 | 0.98 |
| ▸ | HTR2B | P41595 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.98 |
| ▸ | HTR5A | P47898 | 11/20 | 0.64 |
| ▸ | HTR7 | P34969 | 2/20 | 0.64 |
| ▸ | HTR2C | P28335 | 2/20 | 0.64 |
| ▸ | HTR1E | P28566 | 1/20 | 0.64 |
| ▸ | HTR3A | P46098 | 1/20 | 0.64 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 1/20 | 0.52 |
| ▸ | MPO | P05164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2312 | 0.99 | HTR1A (0.96) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL29396422 | 0.99 | HTR1A (1.00) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL3273179 | 0.99 | HTR1A (1.00) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL1957 | 0.99 | HTR1A (1.00) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| SCHEMBL1437 | 0.98 | HTR1A (0.98) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL5042399 | 0.97 | HTR1A (0.96) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL1774275 | 0.94 | HTR1A (0.90) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL2761861 | 0.92 | HTR1A (0.86) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL6444414 | 0.92 | HTR1A (0.86) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL221132 | 0.91 | HTR1A (0.85) | HTR1AHTR2AHTR2BLMNAADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081893-B1 | SUBSTITUTED INDOLES | AUSPEX PHARMACEUTICALS INC (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2081893-A2 | SUBSTITUTED INDOLES | Auspex Pharmaceuticals, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20080103189-A1 | PREPARATION AND UTILITY OF SUBSTITUTED INDOLES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| WO-2008049116-A2 | SUBSTITUTED INDOLES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-04-24 | — | — | WO | disclosed |
| EP-0605697-B1 | INDOL DERIVATIVES FOR THE TREATMENT OF MIGRAINE | ALMIRALL PRODESFARMA SA (ES) | 1999-03-03 | — | — | EP | disclosed |
| US-5565447-A | ALMOTRIPTAN MALATE; TREATING HEADACHES, MOVEMENT DISORDERS, DEPRESSION, ANXIETY | LABORATORIOS ALMIRALL S.A. (ES) | 1996-10-15 | — | — | US | disclosed |
| EP-0605697-A1 | INDOL DERIVATIVES FOR THE TREATMENT OF MIGRAINE | LABORATORIOS ALMIRALL SA (ES) | 1994-07-13 | — | — | EP | disclosed |
| WO-1994002460-A1 | INDOL DERIVATIVES FOR THE TREATMENT OF MIGRAINE | LABORATORIOS ALMIRALL S.A. (ES) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103189-A1 | PREPARATION AND UTILITY OF SUBSTITUTED INDOLES | IDO1, TPH1, IDO2 | HTR1D 71/4885HTR1B 21/4885HTR1F 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.